These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 23570047)
21. Plasmacytoid dendritic cells induce efficient stimulation of antiviral immunity in the context of chronic hepatitis B virus infection. Martinet J; Leroy V; Dufeu-Duchesne T; Larrat S; Richard MJ; Zoulim F; Plumas J; Aspord C Hepatology; 2012 Nov; 56(5):1706-18. PubMed ID: 22707082 [TBL] [Abstract][Full Text] [Related]
22. Serum HBeAg sero-conversion correlated with decrease of HBsAg and HBV DNA in chronic hepatitis B patients treated with a therapeutic vaccine. Wang XY; Zhang XX; Yao X; Jiang JH; Xie YH; Yuan ZH; Wen YM Vaccine; 2010 Nov; 28(51):8169-74. PubMed ID: 20937312 [TBL] [Abstract][Full Text] [Related]
23. Vaccines and immunotherapies against hepatitis B and hepatitis C viruses. Inchauspé G; Michel ML J Viral Hepat; 2007 Nov; 14 Suppl 1():97-103. PubMed ID: 17958650 [TBL] [Abstract][Full Text] [Related]
24. Therapeutic vaccination for chronic hepatitis B. Kosinska AD; Bauer T; Protzer U Curr Opin Virol; 2017 Apr; 23():75-81. PubMed ID: 28453967 [TBL] [Abstract][Full Text] [Related]
25. The ability of Hepatitis B surface antigen DNA vaccine to elicit cell-mediated immune responses, but not antibody responses, was affected by the deglysosylation of S antigen. Xing Y; Huang Z; Lin Y; Li J; Chou TH; Lu S; Wang S Vaccine; 2008 Sep; 26(40):5145-52. PubMed ID: 18462847 [TBL] [Abstract][Full Text] [Related]
26. Therapeutic vaccination for treatment of chronic hepatitis B. Cargill T; Barnes E Clin Exp Immunol; 2021 Aug; 205(2):106-118. PubMed ID: 33969474 [TBL] [Abstract][Full Text] [Related]
27. Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. Yang SH; Lee CG; Park SH; Im SJ; Kim YM; Son JM; Wang JS; Yoon SK; Song MK; Ambrozaitis A; Kharchenko N; Yun YD; Kim CM; Kim CY; Lee SH; Kim BM; Kim WB; Sung YC Gene Ther; 2006 Jul; 13(14):1110-7. PubMed ID: 16525482 [TBL] [Abstract][Full Text] [Related]
28. Cytokine-dependent anti-viral role of CD4-positive T cells in therapeutic vaccination against chronic hepatitis B viral infection. Ren F; Hino K; Yamaguchi Y; Funatsuki K; Hayashi A; Ishiko H; Furutani M; Yamasaki T; Korenaga K; Yamashita S; Konishi T; Okita K J Med Virol; 2003 Nov; 71(3):376-84. PubMed ID: 12966542 [TBL] [Abstract][Full Text] [Related]
29. Cellular and humoral immune response to a third generation hepatitis B vaccine. Schumann A; Fiedler M; Dahmen U; Grosse-Wilde H; Roggendorf M; Lindemann M J Viral Hepat; 2007 Aug; 14(8):592-8. PubMed ID: 17650294 [TBL] [Abstract][Full Text] [Related]
30. Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. Couillin I; Pol S; Mancini M; Driss F; Bréchot C; Tiollais P; Michel ML J Infect Dis; 1999 Jul; 180(1):15-26. PubMed ID: 10353856 [TBL] [Abstract][Full Text] [Related]
31. HBcAg18-27 epitope fused to HIV-Tat 49-57 adjuvanted with CpG ODN induces immunotherapeutic effects in transgenic mice. Wang S; Han Q; Zhang N; Chen J; Liu Z; Zhang G; Li Z Immunol Lett; 2010 Jan; 127(2):143-9. PubMed ID: 19883689 [TBL] [Abstract][Full Text] [Related]
32. Circumventing failed antiviral immunity in chronic hepatitis B virus infection: triggering virus-specific or innate-like T cell response? Koh S; Bertoletti A Med Microbiol Immunol; 2015 Feb; 204(1):87-94. PubMed ID: 25511870 [TBL] [Abstract][Full Text] [Related]
33. Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. Mancini-Bourgine M; Fontaine H; Bréchot C; Pol S; Michel ML Vaccine; 2006 May; 24(21):4482-9. PubMed ID: 16310901 [TBL] [Abstract][Full Text] [Related]
34. Immunotherapeutic interventions in chronic hepatitis B virus infection: a review. Wang L; Zou ZQ; Liu CX; Liu XZ J Immunol Methods; 2014 May; 407():1-8. PubMed ID: 24747918 [TBL] [Abstract][Full Text] [Related]
35. Immunotherapy and therapeutic vaccines for chronic HBV infection. Lang-Meli J; Neumann-Haefelin C; Thimme R Curr Opin Virol; 2021 Dec; 51():149-157. PubMed ID: 34710645 [TBL] [Abstract][Full Text] [Related]
36. Selective functional deficit in dendritic cell--T cell interaction is a crucial mechanism in chronic hepatitis B virus infection. Zheng BJ; Zhou J; Qu D; Siu KL; Lam TW; Lo HY; Lee SS; Wen YM J Viral Hepat; 2004 May; 11(3):217-24. PubMed ID: 15117323 [TBL] [Abstract][Full Text] [Related]
37. Towards immunotherapy for chronic hepatitis B virus infections. Michel ML Vaccine; 2002 Dec; 20 Suppl 4():A83-8. PubMed ID: 12477434 [TBL] [Abstract][Full Text] [Related]
38. Non-antigen-specific and antigen-specific immune therapies for chronic hepatitis B: evidences from laboratory benches and patient's bedsides. Akbar SM; Al-Mahtab M; Khan MS Expert Opin Biol Ther; 2013 Jul; 13(7):1063-74. PubMed ID: 23581572 [TBL] [Abstract][Full Text] [Related]
39. Vaccination with a fusion DNA vaccine encoding hepatitis B surface antigen fused to the extracellular domain of CTLA4 enhances HBV-specific immune responses in mice: implication of its potential use as a therapeutic vaccine. Zhou C; Peng G; Jin X; Tang J; Chen Z Clin Immunol; 2010 Nov; 137(2):190-8. PubMed ID: 20692873 [TBL] [Abstract][Full Text] [Related]
40. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 gene enhanced potency of HBV DNA vaccine. Li X; Yang X; Li L; Liu H; Liu J Vaccine; 2006 Apr; 24(16):3321-31. PubMed ID: 16472546 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]